Stem Cell Therapy and Growth Factor Ovarian in Vitro Activation

Menopause Clinical Trial

— SEGOVA  

Official title:

Platelet Rich Plasma Ovarian in Vitro Activation and Stem Cells Transplantation In Women With Ovarian Failure

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

• NCT number: NCT04009473
• Other study ID #: IRB No 63/295/2015
• Status: Enrolling by invitation
• Phase: Phase 1/Phase 2
• Start date: June 1, 2019
• Est. completion date: December 2021

Study information

• Verified date: August 2020
• Source: Forever Young d.o.o.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.

Description:

The current study seeks to demonstrate how integrative ovarian rejuvenation program called SEGOVA influence the restoration of hormone stability and increase in the number of follicles in ovarian failure patients. The recruitment of patients and data collection would be performed at three sites: The Special Hospital Jevremova Belgrade, Saint James Hospital Malta, and Remedica Skopje Hospital, Macedonia. A 50-100 of Infertile women with ovarian failure will be included in the period between July 2019 - December 2021. The patients would be coded when entering the program, and all personal information would be protected. Information about medical treatment and background will be held on both paper and electronic case report forms.The result of the procedure will be maintained in the research database with blinding to clinical physician that will perform post procedure follow-up of those patients. In case of a complication, possibly related to treatment, the case will be unblinded.

The first day of procedure, autologous platelet rich plasma (PRP) is obtained from 100-120 mL of whole blood. After separation 4 mL of PRP is obtained. Concentration of platelets is optimised on 6-8x baseline and 2-3x leucocytes baseline. For activation of PRP autologous thrombin is used in ratio 1:10.

On the same day the laparoscopic cortical resection of the ovary is performed in standard technique. Ovarian cortex sample is minced in a petri dish.The volume of activated PRP (4 mL) is mixed with ovarian fragments and incubated for the next 48h at 37℃ and 5% CO2. After 48h, the bone marrow sampling from tibia under general anesthesia is performed to obtain bone marrow. After centrifugation the Bone Marrow Aspirate Concentrate (BMAC) with nucleated cells is obtained (3 +/- 1,5 mL).

Finally, after the 48h has passed from ovarian cortex tissue incubation, fragmented tissue of the ovary with 4 mL of PRP will be injected together with 3 +/- 1.5 mL BMAC into the subcortical region of the both ovaries as transvaginal ultra sound guided injection.

After the procedure, during one year follow up, hormone levels of follicle stimulating hormone (FSH), luteinizing hormone (LH),estradiol (E2), progesterone (PG) and anti-mullerian hormone (AMH) would be measured and the follicle numbers would be monitored to provide insight regarding the ovarian function.To investigate the changes in hormone levels, comparisons of the levels detected prior to the intervention, and 3, 6 and 12 months post-intervention, would be performed using Wilcoxon's rank test. Descriptive statistics will be provided for each variable as mean or median number, frequency, percentage, table or graph.

In patients with oocytes retrieved after SEGOVA procedure, standard In Vitro Fertilization protocol would be performed,and fertilization, cleavage and clinical pregnancy rates will be monitored.

Recruitment information / eligibility

• Status: Enrolling by invitation
• Enrollment: 100
• Est. completion date: December 2021
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 25 Years and older

Eligibility

Inclusion Criteria:

Confirmed informed consent, signature and date

• A woman over 25 years of age

• Primary or secondary amenorrhea for at least 3 months

• Hormone Anti Mullerian Hormone values <_0.42 ng / ML and Follicle stimulating hormone FSH> 20 IU / L, and / or failure of previous attempts of assisted reproductive techniques due to limited ovarian response (less than 3 oocyte cells obtained).

• The proper karyotype 46, XX.

• Presence of at least one ovary

Exclusion Criteria:

• Currently pregnancy or breastfeeding

• Presence of Sexually Transmitted Disease (STD positive)

• There is presence of acute infection (C Reactive Protein>5)

• There is an anamnesis or evidence of existing gynecological malignancy

• The presence of adnexal masses indicating the need for further evaluation.

• It has a contraindication to laparoscopic surgery and / or general anesthesia

• Over the past two weeks, use of the following medicines: Oral or systemic corticosteroids, hormones (estrogen, progestins, oral contraceptives), Danazol, anticoagulants, herbal or botanical supplements with potential hormonal effects.

• Type I diabetes mellitus

• Known significant anemia (hemoglobin <8 g / dL), Severe venous thrombosis and / or pulmonary embolism, Cerebrovascular disease, Presence of heart disease, Premature kidney disease (defined as urea in the blood> 30 mg / dL or serum creatinine> 1.6 mg / dL).

Related Conditions & MeSH terms

• Menopause
• Menopause Ovarian Failure
• Menopause, Premature
• Ovarian Failure
• Ovarian Failure Secondary
• Ovarian Failure, Premature
• Ovarian Insufficiency
• Ovarian Insufficiency, Primary
• Premature Birth
• Premature Ovarian Failure
• Premature Ovarian Failure 1
• Premature Ovarian Failure 10
• Premature Ovarian Failure 11
• Premature Ovarian Failure 12
• Premature Ovarian Failure 13
• Premature Ovarian Failure 14
• Premature Ovarian Failure 2A
• Premature Ovarian Failure 2B
• Premature Ovarian Failure 3
• Premature Ovarian Failure 4
• Premature Ovarian Failure 5
• Premature Ovarian Failure 6
• Premature Ovarian Failure 7
• Premature Ovarian Failure 8
• Premature Ovarian Failure 9
• Primary Ovarian Insufficiency

Intervention

Combination Product:
• SEGOVA procedure
SEGOVA procedure includes - Stem cell therapy, G - Growth factor Platelet Plasma Rich therapy and in Vitro Activation of the ovaries.

Locations

Country	Name	City	State
Malta	Saint James Hospital Malta	Sliema
North Macedonia	Re-medika Hospital	Skopje	Macedonia
Serbia	Medigroup Health System, Jevremova hospital	Belgrade

Sponsors (4)

Lead Sponsor	Collaborator
Forever Young d.o.o.	Medigroup Health System, Jevremova hospital, Re-medika Hospital Skoplje, Saint James Hospital Malta

Countries where clinical trial is conducted

Malta,  North Macedonia,  Serbia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Oocyte presence	The numbers of oocytes retrieved after the treatment would be monitored during sonographic follow-ups .	12 months
Primary	Changes in Hormone Levels of Follicle-stimulating hormone FSH (mIU/mL)	Changes in hormonal levels of FSH toward normal ranges would be monitored during one year follow-up procedure.	12 months
Primary	Changes in Hormone Levels of Luteinizing Hormone (mIU/mL)	Changes in hormonal levels of LH toward normal ranges would be monitored during one year follow-up procedure.	12
Primary	Changes in Hormone Levels of Estradiol E2 (pg/mL)	Changes in hormonal levels of E2 toward normal ranges would be monitored during one year follow-up procedure.	12
Primary	Changes in Hormone Levels of Progesterone PG (ng/mL)	Changes in hormonal levels of PG toward normal ranges would be monitored during one year follow-up procedure.	6
Secondary	Fertilization and implantation rate	Following the Ovarian Rejuvenation Treatment, subjects with oocytes retrieved will undergo IVF protocol, and fertilization and cleavage of embryo would be monitored to evaluate fertility outcomes after SEGOVA procedure.	12 months
Secondary	Number of participants with Positive Clinical Pregnancy	Following completion of trial procedure, patients will be monitored for ongoing clinical pregnancies and conceptions, at the site or via post-treatment correspondence.	24 months
Secondary	Changes in total score of The World Health Organization Quality of Life (WHOQOL) BREF modified scale	Change in quality of life total score for each participant post-procedure would be examined and compared to pre-procedure status. The WHOQOL bref questionnaire would be used as a self-report measure of functional health and well-being. Original WHOQOL bref scale uses 26 questions, while our modified version was abbreviated to 18 questions. The WHOQOL-BREF is scored using a Likert scale, with patients choosing to express how much they agree or disagree with a particular statement from 1 to 5 on a response scale. The value 5 indicates they strongly agree, while 1 is disagree. Total score would be obtained as the sum of 18 questions values from 1 to 5, giving minimum value of total score 18, and a maximum score 90.	12 months
Secondary	Changes in anti-Mullerian hormone (AMH) levels (ng/mL)	Changes in AMH levels would be monitored during one year follow-up procedure and compared to the pre-procedure levels.	6 months